Vaxdigm's Technology Background

Background of Vaxdigm

BACKGROUND

Background of Vaxdigm

BACKGROUND

Based on the rapid growth trend of the global advanced biomaterials market toward 2030 (Grand View Research, Biomaterials Market (2026 - 2033)). Target markets by phase include the short-term market focused on B2B business for EGF and FGF, the medium-term market focused on B2C business for EGF and FGF, and the long-term market which aims for business expansion including vaccine technology transfer. The global EGF and FGF market size is projected to grow from $2.39B in 2025 at a CAGR of 9.2%, reaching approximately $3.4B (around 4.6 trillion KRW) by 2030. Taking a conservative approach within this SAM (Serviceable Addressable Market), if Vaxdigm targets a 1% to 2.5% share of the global market by 2030, its market share is calculated to be approximately $73M to $183M (100 billion to 260 billion KRW). The raw material market for pharmaceutical and cosmetic growth factors is a fragmented supply market rather than a monopoly dominated by a single company. There are cases where new entrants have secured a 10% to 30% market share. Therefore, achieving a 2% to 5% market share for our company is considered a conservative and highly realistic goal, especially given our price competitiveness.

* Based on the rapid growth trend of the global advanced biomaterials market toward 2030 (Grand View Research, Biomaterials Market (2026 - 2033)).

* Target markets by phase include the short-term market focused on B2B business for EGF and FGF, the medium-term market focused on B2C business for EGF and FGF, and the long-term market which aims for business expansion including vaccine technology transfer.

* The global EGF and FGF market size is projected to grow from $2.39B in 2025 at a CAGR of 9.2%, reaching approximately $3.4B (around 4.6 trillion KRW) by 2030.

* Taking a conservative approach within this SAM (Serviceable Addressable Market), if Vaxdigm targets a 1% to 2.5% share of the global market by 2030, its market share is calculated to be approximately $73M to $183M (100 billion to 260 billion KRW).

* The raw material market for pharmaceutical and cosmetic growth factors is a fragmented supply market rather than a monopoly dominated by a single company. There are cases where new entrants have secured a 10% to 30% market share. Therefore, achieving a 2% to 5% market share for our company is considered a conservative and highly realistic goal, especially given our price competitiveness.

BACKGROUND

BACKGROUND

ChaperNova™ is applicable to a wide range of fields such as pharmaceuticals, cosmetics, medical devices, and functional foods

Our ChaperNova™ proprietary technology provides a quicker, more efficient alternative with high competitiveness over pre-existing processes.

We are widening our business expansion potential

based on the growing biomaterial market

ChaperNova™ is applicable to a wide range of fields such as pharmaceuticals, cosmetics, medical devices, and functional foods

Our ChaperNova™ proprietary technology provides a quicker, more efficient alternative with high competitiveness over pre-existing processes.